# A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Source: https://onco.cc/trials/nct03816163/  
OnCo record `nct03816163` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zolbetuximab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.

## Summary

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer is a phase 2 interventional study registered as NCT03816163 by Astellas Pharma Global Development, Inc., with 393 participants enrolled, started 2019-03-15 and due to reach its primary completion in 2026-08-31. Interventions recorded: zolbetuximab, nab-paclitaxel and gemcitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03816163
- Phase: 2
- Setting: A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 393

## Sources

- ClinicalTrials.gov NCT03816163: https://clinicaltrials.gov/study/NCT03816163

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Zolbetuximab](https://onco.cc/drugs/zolbetuximab/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct03816163.json